HIMS(Hims & Hers Health, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $271.88M | $526.92M | $872.00M | $1.48B | $2.35B |
| 毛利润 | $204.49M | $408.72M | $714.95M | $1.17B | $1.73B |
| 营业利润 | −$115.04M | −$68.70M | −$29.45M | $61.90M | $105.61M |
| 净利润 | −$107.66M | −$65.68M | −$23.55M | $126.04M | $128.37M |
| 经营现金流 | −$34.41M | −$26.53M | $73.48M | $251.08M | $300.01M |
| 自由现金流 | — | −$33.73M | $46.98M | $198.28M | $57.41M |
| 摊薄每股收益 | $-0.58 | $-0.32 | $-0.11 | $0.53 | $0.51 |